BOPI 07 BR/2023 REPERTOIRE NUMERIQUE 46 (73) JANSSEN PHARMACEUTICA NV, Turnhoutseweg 30, 2340 BEERSE (BE) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and comprising PEG4000 as a surface modifier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection. Fig. 1 Consulter le mémoire ________________________________________ (11) 21080 (51) A61K 39/00 (2018.01); A61K 39/02 (2018.01); A61K 39/39 (2018.01); A61K 47/24 (2018.01); A61K 9/127 (2018.01); A61P 31/04 (2018.01); A61P 43/00 (2018.01) ; C07H 5/06 (2018.01) (21) 1202200537 - PCT/JP2021/023402 (22) 21/06/2021 (30) JP n° 2020-107194 du 22/06/2020 (54) Adjuvant with TLR4 agonist activity. (72) BAN Hitoshi (JP); IMAZAKI Yusuke (JP); TAKANASHI Yosuke (JP) et FUKUSHIMA Akihisa (JP) (73) Sumitomo Pharma Co., Ltd., 6-8, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 5410045 (JP) (74) Cabinet ÉKÉMÉ LYSAGHT SARL, B.P. 6370, YAOUNDE (CM). (57) The present invention relates to a compound that is useful as a vaccine adjuvant, a method for producing the same, a pharmaceutical composition that contains the compound, and use of the compound as vaccine adjuvant.
RkJQdWJsaXNoZXIy MTM1NDc3MA==